AB126 / Aruna Bio - LARVOL DELTA

NEXIS: A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Aruna Bio, Inc.

New P1 trial • Cardiovascular • Ischemic stroke

Serum neurofilament light chain as a biomarker for neural extracellular vesicle therapy in acute ischemic stroke (ISC 2026) - "These results demonstrate the utility of serum NfL as a biomarker for optimizing therapeutic strategies for AIS. Our Phase 1b/2a AIS clinical study will evaluate changes in serum NfL pre- and post-AB126 administration."

Biomarker • Cardiovascular • Ischemic stroke • NEFL

Extracellular Vesicle -based therapeutic for Acute Ischemic Stroke AB126 functions via the CCR2/CCL2 Cell Signaling Pathway (ISC 2026) - "Based on numerous preclinical studies in mice, rats and pig using transcient and permanent MCAO models, AB126 is a viable treatment of AIS and has a cleared IND for AIS. These studies suggest that AB126 functions, at least partially, by the inhibition of the CCL2 signaling pathway and reducing neuroinflammation."

Cardiovascular • Inflammation • Ischemic stroke • CCL2 • CCR2

Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain (GlobeNewswire) - "Aruna Bio, Inc...today announced that the U.S. Patent and Trademark Office has allowed U.S. Patent Application No. 17/238760, entitled Neural Cell Extracellular Vesicles, with method of use claims pertaining to its lead program, AB126, for the treatment of neuro-inflammatory diseases. AB126 is an exosome derived from proprietary neural stem cells and has been shown to reduce inflammation in the brain...This patent contains broad claims for the method of using AB126 to treat multiple indications where neuroinflammation is the primary pathological driver of the neurological disease."

Patent • Alzheimer's Disease • CNS Disorders • Parkinson's Disease